Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $10.53

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $10.53.

A number of brokerages recently commented on SAGE. Scotiabank decreased their target price on shares of Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, October 30th. Stifel Nicolaus decreased their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research report on Monday, December 16th. Oppenheimer decreased their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating on the stock in a research report on Wednesday, October 30th. StockNews.com cut shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, November 20th.

Institutional Investors Weigh In On Sage Therapeutics

Several hedge funds have recently bought and sold shares of the business. RTW Investments LP boosted its stake in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock worth $40,372,000 after acquiring an additional 111,123 shares in the last quarter. State Street Corp boosted its stake in Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after acquiring an additional 451,377 shares in the last quarter. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after acquiring an additional 3,757 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Sage Therapeutics by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company's stock worth $2,510,000 after acquiring an additional 10,116 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Sage Therapeutics by 11.3% during the third quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company's stock worth $1,343,000 after acquiring an additional 18,814 shares in the last quarter. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Price Performance

NASDAQ:SAGE traded down $0.03 during trading hours on Thursday, reaching $7.25. The company's stock had a trading volume of 1,222,927 shares, compared to its average volume of 2,832,859. The firm has a 50-day simple moving average of $6.25 and a 200-day simple moving average of $7.04. Sage Therapeutics has a 1 year low of $4.62 and a 1 year high of $27.39.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.